Physician profile
Daniel A Barrera
NPI 1043693823
$45,832.57
in general payments reported to CMS, 2019-2025
12 companies · $3,618 in 2025
The $3,618 reported for 2025 was more than what 87% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15K · 2023: $22K · 2024: $4,569 · 2025: $3,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $25K · Food and Beverage: $3,394 · Travel and Lodging: $2,259 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $25,000.00 |
| Food and Beverage | $3,393.62 |
| Travel and Lodging | $2,259.26 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $42,836.06 | 2022-2025 | Da Vinci Surgical System, Davinci Xi |
| Histosonics, INC. | $1,023.83 | 2024-2025 | |
| Davol INC. | $498.35 | 2023-2025 | Phasix Mesh |
| Ethicon US, LLC | $399.94 | 2023-2025 | Neuwave, Certus 140, Mega Soft |
| Boston Scientific Corporation | $300.22 | 2024-2025 | Therasphere Administration Set, General - Pain Management |
| Medtronic, INC. | $298.37 | 2023-2025 | Progrip, Dextile |
| Tela Bio, INC. | $169.01 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Smith+Nephew, INC. | $156.54 | 2022 | |
| Kci USA, INC. | $100.84 | 2022 | |
| Braintree Laboratories, INC. | $18.50 | 2022 | |
| Glaxosmithkline, LLC. | $15.46 | 2024 | Bexsero |
| Bioventus LLC | $15.45 | 2024 | Bonescalpel & Sonicone (O.R.) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.